Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1996 2
1997 5
1998 6
1999 2
2001 13
2002 5
2003 7
2004 4
2005 8
2006 7
2007 13
2008 10
2009 8
2010 6
2011 10
2012 18
2013 7
2014 6
2015 5
2016 5
2017 6
2018 7
2019 7
2020 3
2021 5
2022 4
2023 8
2024 15
2025 7
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Results by year

Filters applied: . Clear all
Page 1
Ceramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment.
Draelos ZD, Baalbaki N, Colon G, Dreno B. Draelos ZD, et al. J Drugs Dermatol. 2023 Jun 1;22(6):554-558. doi: 10.36849/JDD.7142. J Drugs Dermatol. 2023. PMID: 37276158 Clinical Trial.
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl peroxide (2.5%)(A/BPO), which utilizes a retinoid to normalize follicular keratinization and BPO to decrease the C. acnes population. ...
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl peroxide ( …
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Stein Gold L, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, Lain E, Gold M, Beer K, Draelos Z, Sadick N, Pillai R, Bhatt V, Tanghetti EA. Stein Gold L, et al. Am J Clin Dermatol. 2022 Jan;23(1):93-104. doi: 10.1007/s40257-021-00650-3. Epub 2021 Oct 21. Am J Clin Dermatol. 2022. PMID: 34674160 Free PMC article. Clinical Trial.
OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne. METHODS: In a phase II, double-blind, multicenter, randomized, …
OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxi …
Efficacy of ceramides and niacinamide-containing moisturizer versus hydrophilic cream in combination with topical anti-acne treatment in mild to moderate acne vulgaris: A split face, double-blinded, randomized controlled trial.
Tempark T, Shem A, Lueangarun S. Tempark T, et al. J Cosmet Dermatol. 2024 May;23(5):1758-1765. doi: 10.1111/jocd.16212. Epub 2024 Feb 1. J Cosmet Dermatol. 2024. PMID: 38299457 Clinical Trial.
INTRODUCTION: Topical therapy is the mainstay treatment of acne, and topical retinoids such as tretinoin, tazarotene, and adapalene are recommended as the first-line therapy for mild to moderate acne. However, the cutaneous irritations may occur, and the dermocosmetics are …
INTRODUCTION: Topical therapy is the mainstay treatment of acne, and topical retinoids such as tretinoin, tazarotene, and adapalene a …
Evaluating the Effectiveness of Probiotic Supplementation in Combination With Doxycycline for the Treatment of Moderate Acne: A Randomized Double-Blind Controlled Clinical Trial.
Atefi N, Mohammadi M, Bodaghabadi M, Mehrali M, Behrangi E, Ghassemi M, Jafarzadeh A, Goodarzi A. Atefi N, et al. J Cosmet Dermatol. 2025 Jan;24(1):e16614. doi: 10.1111/jocd.16614. Epub 2024 Oct 16. J Cosmet Dermatol. 2025. PMID: 39410868 Free PMC article. Clinical Trial.
All patients received the same topical treatment, which consisted of a daily antibacterial face wash and Adapalene gel every other night. The control group received one capsule of doxycycline (100 mg) daily, whereas the intervention group received one probiotic capsule dai …
All patients received the same topical treatment, which consisted of a daily antibacterial face wash and Adapalene gel every other ni …
Effectiveness and tolerability of adapalene cream 0.1% in the treatment of female skin ageing: A randomised controlled trial.
Tran QT, Le DV, Vu YH, Le MH, Vu LH, Le DH, Vu MN. Tran QT, et al. Indian J Dermatol Venereol Leprol. 2025 Sep-Oct;91(5):571-576. doi: 10.25259/IJDVL_673_2024. Indian J Dermatol Venereol Leprol. 2025. PMID: 40990960 Free article. Clinical Trial.
Background Adapalene has been used off-label by dermatologists to manage skin ageing. Objectives To evaluate the effectiveness and tolerability of adapalene cream 0.1% in the treatment of skin ageing. ...Subjects were randomly assigned to either adapalene cre …
Background Adapalene has been used off-label by dermatologists to manage skin ageing. Objectives To evaluate the effectiveness and to …
Investigation of the effect of adapalene 0.3%/benzoyl peroxide 2.5% gel in Korean patients with acne: a randomized, double-blind clinical trial, with a histopathological and immunohistochemical study.
Lee JH, Kim DH, Yoon JY, Kim TM, Kim SR, Suh DH. Lee JH, et al. Ital J Dermatol Venerol. 2024 Aug;159(4):444-452. doi: 10.23736/S2784-8671.24.07800-9. Ital J Dermatol Venerol. 2024. PMID: 39069843 Clinical Trial.
BACKGROUND: Acne vulgaris poses significant physical and psychological challenges worldwide. Data of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) for acne treatment in Asian patients is limited. ...
BACKGROUND: Acne vulgaris poses significant physical and psychological challenges worldwide. Data of adapalene 0.3%/benzoyl peroxide …
Efficacy and Safety of Clascoterone Cream 1% and Adapalene Gel 0.3% in Patients With Acne.
Kircik L, Lamb AJ, Kircik A, Squittieri N, Kyeremateng K. Kircik L, et al. J Drugs Dermatol. 2026 Jun 1;25(6):545-550. doi: 10.36849/JDD.9761. J Drugs Dermatol. 2026. PMID: 42235048 Clinical Trial.
This 20-week, open-label, pilot study (NCT06336603) evaluated the efficacy and safety of clascoterone cream 1% combined with adapalene gel 0.3% in patients with acne. METHODS: Patients aged ≥12 years with moderate-to-severe acne applied clascoterone cream 1% twice d …
This 20-week, open-label, pilot study (NCT06336603) evaluated the efficacy and safety of clascoterone cream 1% combined with adapalene …
Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: A Pooled Analysis by Age.
Kircik LH, Harper JC, Baldwin H, Eichenfield LF, Tanghetti EA, Graber E, Woolery-Lloyd HC, Guenin E, Draelos ZD. Kircik LH, et al. J Drugs Dermatol. 2025 Dec 1;24(12):1186-1194. doi: 10.36849/JDD.9407. J Drugs Dermatol. 2025. PMID: 41329145 Clinical Trial.
Fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel demonstrated superior efficacy to vehicle and component dyads with good safety/tolerability in 3 clinical trials of acne. ...
Fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel demonstrated superior efficacy to vehicle and c …
Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis.
Callender VD, Baldwin H, Gold LS, Cook-Bolden FE, Guenin E, Alexis AF. Callender VD, et al. J Dermatolog Treat. 2025 Dec;36(1):2480232. doi: 10.1080/09546634.2025.2480232. Epub 2025 Mar 23. J Dermatolog Treat. 2025. PMID: 40122140 Free article. Clinical Trial.
INTRODUCTION: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination approved for acne. ...
INTRODUCTION: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination a …
Efficacy and Safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel in Facial Acne Vulgaris: A Randomized, Controlled Clinical Trial.
Maiti R, Sirka CS, Ashique Rahman MA, Srinivasan A, Parida S, Hota D. Maiti R, et al. Clin Drug Investig. 2017 Nov;37(11):1083-1091. doi: 10.1007/s40261-017-0568-2. Clin Drug Investig. 2017. PMID: 28913735 Clinical Trial.
After randomization one group (n = 30) received tazarotene 0.1% plus clindamycin 1% gel and another group (n = 30) received adapalene 0.1% plus clindamycin 1% gel for 1 month. At follow-up, all the parameter were reassessed. ...A 50% reduction in the total lesion count fr …
After randomization one group (n = 30) received tazarotene 0.1% plus clindamycin 1% gel and another group (n = 30) received adapalene …
193 results